Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…
News
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all…
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all…
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies…
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies…
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response…
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response…
TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project
ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project
ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical…
European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical…
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
FARMINGTON HILLS, Mich., June 27, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
FARMINGTON HILLS, Mich., June 27, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…